Health Condition 1: A150- Tuberculosis of lung
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Newly diagnosed drug-sensitive tuberculosis (DSTB) patients, pulmonary or extra-pulmonary, aged 18 years and above, willing to participate and provide written informed consent.
Exclusion criteria
Exclusion criteria: Patients will be excluded if they have drug-resistant tuberculosis (MDR/XDR), are HIV-positive, have chronic kidney disease evidenced by elevated serum creatinine levels or have significant chronic liver disease. Patients will also be excluded if they have known hypercalcemia, a history of vitamin D toxicity, granulomatous diseases such as sarcoidosis, primary hyperparathyroidism, or malignancies associated with hypercalcemia (e.g., lymphoma, multiple myeloma). Individuals currently taking vitamin D supplements, those on digitalis (digoxin) therapy, pregnant or lactating women, and patients with a known hypersensitivity to vitamin D preparations will also be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Higher sputum smear conversion rates and improved overall treatment success rate. Timepoint: Sputum smear microscopy will be performed at- 2 months and at 6 months, to assess conversion from smear-positive to smear-negative status. | — |
Secondary
| Measure | Time frame |
|---|---|
| Greater weight gain, improvement in other clinical symptoms, monitoring & recording of any adverse events.Timepoint: Outcome parameters will be assessed at baseline prior to treatment initiation, at 4 weeks, 8 weeks & monthly thereafter at 12, 16, 20 & 24 weeks, including at the point of treatment completion at 6 months. | — |
Countries
India
Contacts
GMERS medical college, Gotri.